Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.

Habashy DA, El Tayebi HM, Fawzy IO, Hosny KA, Esmat G, Abdelaziz AI.

World J Hepatol. 2016 Aug 18;8(23):976-84. doi: 10.4254/wjh.v8.i23.976.

2.

Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

El Tayebi HM, Abdelaziz AI.

World J Gastroenterol. 2016 Mar 7;22(9):2668-77. doi: 10.3748/wjg.v22.i9.2668. Review.

3.

Restitution of gene expression and histone acetylation signatures altered by hepatitis B virus through antiviral microRNA-like molecules in nontransformed murine hepatocytes.

Jenke AC, Hensel KO, Klein A, Willuhn L, Prax S, Weil PP, Winkler T, Deba T, Orth V, Baiker A, Wirth S, Postberg J.

Clin Epigenetics. 2014 Nov 14;6(1):26. doi: 10.1186/1868-7083-6-26. eCollection 2014.

4.

Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.

Yulyana Y, Ho IA, Sia KC, Newman JP, Toh XY, Endaya BB, Chan JK, Gnecchi M, Huynh H, Chung AY, Lim KH, Leong HS, Iyer NG, Hui KM, Lam PY.

Mol Ther. 2015 Apr;23(4):746-56. doi: 10.1038/mt.2015.13. Epub 2015 Jan 26.

5.

Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Enguita-Germán M, Fortes P.

World J Hepatol. 2014 Oct 27;6(10):716-37. doi: 10.4254/wjh.v6.i10.716. Review.

6.

The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.

Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R.

Infect Agent Cancer. 2014 Aug 20;9:27. doi: 10.1186/1750-9378-9-27. eCollection 2014. Review.

7.

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB.

J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14.

8.

Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Aleem E, Elshayeb A, Elhabachi N, Mansour AR, Gowily A, Hela A.

Oncol Lett. 2012 Mar;3(3):704-712. Epub 2011 Dec 30.

9.

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G.

Oncotarget. 2012 Mar;3(3):236-60. Review.

10.

Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases.

Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, Xu Z, Teng L, Zhu T.

PLoS One. 2011;6(12):e28384. doi: 10.1371/journal.pone.0028384. Epub 2011 Dec 2.

11.

Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma.

Walker EJ, Rosenberg SA, Wands JR, Kim M.

For Immunopathol Dis Therap. 2011;2(2):195-204.

12.

Tea catechins as inhibitors of receptor tyrosine kinases: mechanistic insights and human relevance.

Larsen CA, Dashwood RH, Bisson WH.

Pharmacol Res. 2010 Dec;62(6):457-64. doi: 10.1016/j.phrs.2010.07.010. Epub 2010 Aug 4. Review.

13.

Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Breuhahn K, Schirmacher P.

World J Gastroenterol. 2008 Mar 21;14(11):1690-8. Review.

14.

Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY.

World J Gastroenterol. 2005 Aug 14;11(30):4655-60.

15.

Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation.

Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E, Ono T, Koide N.

BMC Cancer. 2005 Jan 20;5:9.

16.

Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3.

Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H.

Cancer Res. 2004 Nov 1;64(21):7711-23.

17.

Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A.

Gut. 2004 Aug;53(8):1180-9.

18.
19.

Supplemental Content

Support Center